-transparent.png){kind=logo}
The aliphatic dicarboxylic acid surprisingly afforded potent cytotoxicity and in vivo antineoplastic activity. The agents were active against the growth of a variety of leukemias, lymphomas, and suspended HeLa uterine carcinoma. Suppression of growth of cell lines derived from human solid cancers, e.g. SW-480 colon adenocarcinoma, lung MB- 9812, glioma HS-683, and rat osteosarcoma UMR-106 was observed. A mode of action study in L1210 lymphoid leukemia demonstrated that DNA and RNA syntheses were inhibited at multiple sites including ribonucleoside reductase, purine de novo synthesis at PRPP-amidotransferase and IMP dehydrogenase and nucleic acid kinases. These studies could not exclude the possibility that the agents also interacted with the DNA molecule itself interfering with the utilization of the template.
I H Hall, and
R A Izydore, and
A E Warren, and
C R Barnes
November 1970,
Cancer research,
I H Hall, and
R A Izydore, and
A E Warren, and
C R Barnes
December 1990,
Pharmaceutical research,
I H Hall, and
R A Izydore, and
A E Warren, and
C R Barnes
February 1976,
Lakartidningen,
I H Hall, and
R A Izydore, and
A E Warren, and
C R Barnes
May 1946,
The Journal of organic chemistry,
I H Hall, and
R A Izydore, and
A E Warren, and
C R Barnes
January 1954,
Hoppe-Seyler's Zeitschrift fur physiologische Chemie,
I H Hall, and
R A Izydore, and
A E Warren, and
C R Barnes
August 1952,
The Journal of pharmacy and pharmacology,
I H Hall, and
R A Izydore, and
A E Warren, and
C R Barnes
January 1983,
Drug and chemical toxicology,
I H Hall, and
R A Izydore, and
A E Warren, and
C R Barnes
March 1984,
Cancer treatment reports,
I H Hall, and
R A Izydore, and
A E Warren, and
C R Barnes
May 1979,
Cancer research,
I H Hall, and
R A Izydore, and
A E Warren, and
C R Barnes
January 1957,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
